AstraZeneca licenses CSPC’s cardiovascular drug in $2 billion deal
The big pharma company AstraZeneca has forged a licensing pact worth $2 billion with the Chinese firm CSPC Pharmaceutical Group for access to an experimental small molecule treatment for dyslipidemia.